Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06073119 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
NCT06073119 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 221 participants.
The verdict
NCT06073119, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
Study Summary
This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details included a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (4 weeks ± 3 days). The total number of study visits was 7.
Interventions
- DRUG Placebo
- DRUG SAR441566
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2023-10-26 |
| Est. Completion | 2024-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06073119
The ClinicalTrials.gov registry entry for NCT06073119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06073119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06073119 about?
NCT06073119 is a clinical study titled "A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis". This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study detail...
What is the current status of trial NCT06073119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2023-10-26. Estimated completion is 2024-12-11.
What interventions are being tested in trial NCT06073119?
The interventions under investigation include: Placebo (DRUG), SAR441566 (DRUG).
Who is sponsoring clinical trial NCT06073119?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.